PMID- 28923637
OWN - NLM
STAT- MEDLINE
DCOM- 20180430
LR  - 20220317
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 49
IP  - 8
DP  - 2017 Oct
TI  - Ledipasvir + Sofosbuvir for Liver Transplant Recipients With Recurrent Hepatitis 
      C: A Systematic Review and Meta-analysis.
PG  - 1855-1863
LID - S0041-1345(17)30526-2 [pii]
LID - 10.1016/j.transproceed.2017.04.014 [doi]
AB  - INTRODUCTION: Studies focusing on the efficacy and safety of ledipasvir (LDV) + 
      sofosbuvir (SOF) therapy in liver transplant (LT) recipients with hepatitis C 
      virus (HCV) recurrence are still limited. Therefore, the aim of our work was to 
      perform a systematic review and meta-analysis to evaluate outcome data of LDV + 
      SOF therapy in LT recipients. METHODS: Multiple databases were systematically 
      searched for eligible studies. We included studies reporting sustained 
      virological response 12 weeks after treatment (SVR12) and treatment-related 
      adverse events (AEs) in LT recipients treated with LDV + SOF +/- ribavirin (RBV) 
      for HCV recurrence. All statistical analyses were conducted by using R version 
      3.3.1 (The R Foundation for Statistical Computing, Vienna, Austria). RESULTS: 
      Twelve studies with a total of 994 LT recipients were included, most of which 
      were diagnosed with HCV genotype 1 infection. The overall SVR12 reached 96.3% 
      (95% confidence interval [CI]: 94.9%-97.5%) and no significant heterogeneity was 
      observed (Q statistic = 10.63, P = .47; I(2) = 0%). No difference was found in 
      SVR12 between treatments for 12 weeks and 24 weeks (P = .18). Patients treated 
      with LDV + SOF + RBV (n = 525) exhibited an SVR12 rate of 95.1% (95% CI 
      92.8%-96.6%), which showed no difference from the findings in the LDV + SOF 
      treatment group (n = 314) with an SVR12 reaching 94.9% (95% CI 91.5%-97.0%; P = 
      .92). There was a tendency for a higher SVR12 in patients without cirrhosis than 
      those with cirrhosis (P < .05). The most common AEs were listed as following: 
      anemia 41.9% (n = 203 of 484), fatigue 39.1% (n = 207 of 530), headache 24.2% 
      (n = 128 of 530), nausea 21.9% (n = 106 of 484), and diarrhea 19.0% (n = 92 of 
      484). CONCLUSION: LDV + SOF-based treatment is highly effective and well 
      tolerated in LT recipients with HCV reinfection.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Liao, H-T
AU  - Liao HT
AD  - Department of Liver Surgery, Liver Transplantation Division, West China Hospital, 
      Sichuan University, Chengdu, China.
FAU - Tan, P
AU  - Tan P
AD  - Department of Urology, Institute of Urology, West China Hospital, Sichuan 
      University, Chengdu, China.
FAU - Huang, J-W
AU  - Huang JW
AD  - Department of Liver Surgery, Liver Transplantation Division, West China Hospital, 
      Sichuan University, Chengdu, China. Electronic address: huangjiweimd@foxmail.com.
FAU - Yuan, K-F
AU  - Yuan KF
AD  - Department of Liver Surgery, Liver Transplantation Division, West China Hospital, 
      Sichuan University, Chengdu, China. Electronic address: ykf13@163.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
RN  - 0 (Antiviral Agents)
RN  - 0 (Benzimidazoles)
RN  - 0 (Fluorenes)
RN  - 0 (ledipasvir, sofosbuvir drug combination)
RN  - 49717AWG6K (Ribavirin)
RN  - E2OU15WN0N (Uridine Monophosphate)
RN  - WJ6CA3ZU8B (Sofosbuvir)
SB  - IM
MH  - Antiviral Agents/*therapeutic use
MH  - Benzimidazoles/*therapeutic use
MH  - Fluorenes/*therapeutic use
MH  - Hepatitis C, Chronic/*drug therapy
MH  - Humans
MH  - Recurrence
MH  - Ribavirin/therapeutic use
MH  - Sofosbuvir
MH  - Uridine Monophosphate/*analogs & derivatives/therapeutic use
EDAT- 2017/09/20 06:00
MHDA- 2018/05/01 06:00
CRDT- 2017/09/20 06:00
PHST- 2016/12/23 00:00 [received]
PHST- 2017/04/15 00:00 [revised]
PHST- 2017/04/27 00:00 [accepted]
PHST- 2017/09/20 06:00 [entrez]
PHST- 2017/09/20 06:00 [pubmed]
PHST- 2018/05/01 06:00 [medline]
AID - S0041-1345(17)30526-2 [pii]
AID - 10.1016/j.transproceed.2017.04.014 [doi]
PST - ppublish
SO  - Transplant Proc. 2017 Oct;49(8):1855-1863. doi: 
      10.1016/j.transproceed.2017.04.014.